Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

ClinicalTrials.gov ID: NCT02268214

Public ClinicalTrials.gov record NCT02268214. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus

Study identification

NCT ID
NCT02268214
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
833 participants

Conditions and interventions

Interventions

  • Dapagliflozin Drug
  • Placebo for dapagliflozin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 10, 2014
Primary completion
Jan 3, 2017
Completion
Aug 24, 2017
Last update posted
Sep 12, 2018

2014 – 2017

United States locations

U.S. sites
36
U.S. states
20
U.S. cities
36
Facility City State ZIP Site status
Research Site Little Rock Arkansas 72205
Research Site Encino California 91436
Research Site La Mesa California 91942
Research Site San Diego California 92161
Research Site Tarzana California 91356
Research Site Torrance California 90502
Research Site Aurora Colorado 80045
Research Site Denver Colorado 80220
Research Site Cooper City Florida 33024
Research Site Jacksonville Florida 32258
Research Site Miami Florida 33136
Research Site Port Orange Florida 32127
Research Site Idaho Falls Idaho 83404-7596
Research Site Des Moines Iowa 50314
Research Site Louisville Kentucky 40213
Research Site Portland Maine 04101
Research Site Hyattsville Maryland 20782
Research Site Rockville Maryland 20852
Research Site Kalamazoo Michigan 49008
Research Site Minneapolis Minnesota 55416
Research Site Chesterfield Missouri 63017
Research Site Las Vegas Nevada 89148
Research Site Albany New York 12206
Research Site Buffalo New York 14215
Research Site Asheville North Carolina 28803
Research Site Chapel Hill North Carolina 27517
Research Site Greenville North Carolina 27834
Research Site Morehead City North Carolina 28557
Research Site Langhorne Pennsylvania 19047
Research Site Kingsport Tennessee 37660
Research Site Nashville Tennessee 37212
Research Site Amarillo Texas 79106
Research Site Dallas Texas 75230
Research Site Houston Texas 77090
Research Site Salt Lake City Utah 84108
Research Site Olympia Washington 98502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02268214, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 12, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02268214 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →